SSKN earnings analysis
What we found in SSKN's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
STRATA positions itself as a phototherapy-focused med‑tech company centered on its XTRAC excimer laser recurring‑revenue model (842 systems in the U.S. recurring program as of December 31, 2025). Gross economics are strong (multiple quarters at ~60% gross margin), management highlights regulatory/reimbursement changes (CPT descriptor revisions effective January 1, 2027) that could expand addressable indications, but revenue slipped year‑over‑year and cash burn / free cash flow remain negative despite a profitable operating quarter in Q4 2025. Key strategic assets: FDA 510(k) cleared XTRAC/VTRAC devices, TheraClear acquisition (Jan 2022), 16 U.S. patents in force or pending and an ISO 13485 17,000 sq. ft. manufacturing facility in Carlsbad.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Scale in recurring‑revenue model
- Company reports 842 XTRAC systems were included in its U.S. dermatology recurring procedures revenue model as of December 31, 2025 (Business—'we estimate ... 842 systems were, as of December 31, 2025, included in our dermatology recurring procedures revenue model').
- Sustained gross margins (~60%)
- Multiple recent quarters show gross margin around 60% (for example, Q3 and Q4 2025 gross margin 60.4% each per quarterly results), supporting attractive unit economics for procedures revenue.
- Positive operating inflection in Q4 2025
- Q4 2025 shows an operating margin of 12.6% and GAAP diluted EPS of $0.13 (quarterly financial history), indicating an operational inflection versus prior quarters.
- Reimbursement expansion potential (CPT changes)
- Filing notes national CPT reimbursement in 2025 ranged $137–$183 per treatment and states revised CPT descriptors effective January 1, 2027 (CPT 96920–96922) may broaden Medicare reimbursement eligibility (Business—'the national CPT code reimbursement ... ranged ... between $137 per treatment to $183 per treatment for 2025' and 'revised CPT code descriptors effective January 1, 2027').
- Regulatory clearances and IP
- XTRAC and TheraClear are FDA 510(k) cleared and the Company reports 16 issued U.S. patents in force or pending as of December 31, 2025 (Business—'we have received FDA 510(k) clearance...' and 'As of December 31, 2025, 16 issued U.S. patents are in force or pending').
- Owned manufacturing capacity
- Company manufactures XTRAC at a 17,000 sq. ft. ISO 13485‑certified facility in Carlsbad, CA and states current capacity is sufficient for foreseeable demand (Business—'We manufacture our XTRAC products at our 17,000 sq. ft. facility ... ISO 13485 compliant').
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue decline year‑over‑year
- Quarterly results sum to roughly $34.0M in 2024 (7+8+9+10) versus $31.0M in 2025 (7+8+7+9), indicating a revenue decline year over year (quarterly financial history).
- Worsening free cash flow / cash burn
- Free cash flow by quarter shows FY2024 roughly -$1.919M (-2.0 +0.246 -0.364 +0.199) versus FY2025 roughly -$4.300M (-0.749 -2.0 -1.0 -0.551), i.e., larger negative FCF in 2025 (quarterly financial history).
- Exposure to U.S. tariffs and trade policy
- Filing explicitly warns that 2025 U.S. trade policy actions increased import tariffs and that increased tariffs could adversely affect revenues, costs or gross profit in the Dermatology Procedures Equipment segment ('In 2025, the U.S. introduced trade policy actions that have increased import tariffs ... the revenues, costs, or gross profit ... may be adversely affected').
- Reimbursement uncertainty until 2027
- Although CMS confirmed continued reimbursement under existing CPT codes through December 31, 2026, the filing states future reimbursement levels and coverage determinations remain subject to CMS rulemaking and third‑party payer policies (Business—'CMS confirmed continued reimbursement ... through December 31, 2026' and 'future reimbursement levels and coverage determinations remain subject to CMS rulemaking and third‑party payer policies').
- Thin R&D resources limit pipeline
- The Company reports its R&D team consists of two employees, which constrains new product development and engineering capacity ('Our research and development team, including engineers, consists of two employees').
- IP validity risk
- While the Company cites 16 U.S. patents in force or pending, it discloses that patent validity and enforceability can be challenged and if invalidated could reduce competitive advantage ('we cannot be certain that, if challenged, our patented methods and apparatus ... would be upheld').
What they reported.
What the company itself reported, taken out of the document.
- Segment
- Dermatology recurring procedures (XTRAC) - U.S. recurring revenue model (842 systems as of 12/31/2025)
- Segment
- Dermatology equipment sales and international recurring (VTRAC and equipment distributors)
- Segment
- TheraClear acne therapy system (acquired Jan 2022)
What they said about what is next.
The 10‑K does not provide numeric FY26 revenue or EPS guidance; MD&A discusses reimbursement timing and risks (e.g., CPT descriptor changes effective Jan 1, 2027) but no explicit numeric annual outlook is given. Annual outlook appears deferred to quarterly earnings releases/calls.
The filing reads about the same as the one before it.
What came before.
- 10-Q · November 14, 2025
- STRATA reported Q3 2025 revenue of $6,929,000 and GAAP loss per share of $(0.36). Revenue declined versus both prior year (Q3 2024: $8,797,000) and prior quarter, while gross margin remained healthy at ~60.4% and net…
- 10-Q · August 14, 2025
- STRATA Skin Sciences missed consensus in Q2: revenue of $7,663 (thousands) and GAAP EPS of $(0.60), with operating loss and cash usage widening year-over-year. Management says existing cash and expected revenues should…
- 10-K · March 28, 2025
- STRATA Skin Sciences positions itself as a niche medical‑technology company in dermatology built around its XTRAC excimer laser franchise, a recurring‑procedure revenue model (864 systems in the recurring model as of…
- 10-Q · November 14, 2024
- STRATA reported Q3 revenue of $8,797,000, essentially flat versus $8,852,000 in Q3 2023 (down $55,000) and above the street. Gross profit remained strong at $5,307,000 (≈60.3% gross margin) but operating loss widened to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SSKN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever